Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In Route of Administration, the Injectable/Parenteral segment led the market with approximately 49.5% market share in 2025 mainly attributed to its existing clinical application and robust product portfolio, while the Oral segment is expected to witness the fastest CAGR of 13% in the forecast period on account of increasing patient convenience and compliance
In this study, we evaluated various copper compounds at cellular, genomic and proteomic levels using HaCaT keratinocytes
If youre curious about how GLP-1s may impact your ADHD symptoms, talk to your health care provider
Clinical trial starting doses The landmark phase 2 trial published in the New England Journal of Medicine randomized 338 participants across multiple dose groups
Antibodies to IF or PCs cause anemia
Discover how genetic mutations cause the von Willebrand factor not to perform as it should
US$ 26.05
US$ 26.50
US$ 22.19
US$ 21.79
US$ 26.40
